Cochlear is the global leader in implantable hearing solutions with products including cochlear implants, bone conduction implants and acoustic implants. Cochlear commenced operations in 1981 as part of the Nucleus group and in 1995 listed on the Australian Securities Exchange (ASX). Today, Cochlear is a Top 50 ASX-listed company with annual global revenues exceeding AUD$1.4 billion.
Cochlear aims to support cochlear implantation becoming the standard of care for people with severe to profound hearing loss. Cochlear also provides bone conduction implants for people with conductive hearing loss, mixed hearing loss and single sided deafness. Cochlear has provided more than 600,000 implantable devices, helping people of all ages to hear. Whether these hearing solutions were implanted today or many years ago, Cochlear strives to continuously develop new technologies and innovations for all recipients. Cochlear invests more than AUD$180 million each year in research and development and currently participates in over 100 collaborative research programs worldwide.
Cochlear’s global headquarters are on the campus of Macquarie University in Sydney, Australia with regional headquarters in Asia Pacific, Europe and the Americas. Cochlear has a significant international footprint, selling in over 180 countries, and a global workforce of more than 4,000 employees.
Cochlear strives to help people “Hear now. And always” – aiming to provide them with a lifetime of hearing through the best possible support.